Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,166

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Targeting lactate metabolism for cancer therapeutics

Open access
Doherty, Joanne R., Cleveland, John L. · 2013 · Journal of Clinical Investigation

Abstract

Lactate, once considered a waste product of glycolysis, has emerged as a critical regulator of cancer development, maintenance, and metastasis.Indeed, tumor lactate levels correlate with increased metastasis, tumor recurrence, and poor outcome.Lactate mediates cancer cell intrinsic effects on metabolism and has additional non-tumor cell autonomous effects that drive tumorigenesis.Tumor cells can metabolize lactate as an energy source and shuttle lactate to neighboring cancer cells, adjacent stroma, and vascular endothelial cells, which induces metabolic reprogramming.Lactate also plays roles in promoting tumor inflammation and in functioning as a signaling molecule that stimulates tumor angiogenesis.Here we review the mechanisms of lactate production and transport and highlight emerging evidence indicating that targeting lactate metabolism is a promising approach for cancer therapeutics. Lactate homeostasis in cancer cellsCancer cells are programmed to rely on aerobic glycolysis to support their proliferation and anabolic growth, an observation known as the Warburg effect (1, 2).Aerobic glycolysis rapidly generates ATP and diverts carbon from glucose into precursors for the synthesis of nucleotides, proteins, and lipids.As a consequence of this switch, glucose is preferentially catabolized to lactate, rather than fully metabolized to carbon dioxide via mitochondrial oxidative phosphorylation (OXPHOS).Glutamine catabolism by cancer cells also supports anabolic growth, sustains TCA cycle intermediates, and regulates redox homeostasis (3-5).These activities augment lactate production, albeit to a lesser extent than the lactate derived from glucose catabolism.Specifically, glutaminase (GLS) directs the conversion of glutamine to glutamate, which is then converted to α-ketoglutarate (αKG) by glutamate dehydrogenase that enters the TCA cycle.Malate that is then generated from αKG can exit the TCA cycle and be converted to pyruvate by malic enzyme (ME), which contributes to redox homeostasis via NADPH production.An alternate use of glutamine in pancreatic ductal carcinomas involves the transamination of glutamate and oxaloacetate (OAA) to αKG and aspartate (5).Aspartate exits the mitochondria and is transaminated back to OAA and glutamate; OAA is then converted to malate and subsequently to pyruvate.Finally, pyruvate is converted to lactate by the enzyme lactate dehydrogenase A (LDHA, Figure 1).Oncogenic lesions in cancer drive the switch to aerobic glycolysis and lactate production by inducing the expression and activation of several glycolytic enzymes (Figure 1).First, aberrant PI3K/AKT signaling induces the expression and cell surface expression of high-affinity glucose transporters (i.e., GLUT1 and GLUT4) and the activation of hexokinase 2 (HK2) and 6-phosphofructokinase 1 (PFK1) (6-8).Second, the transcriptional oncoproteins MYC and HIF-1α induce the expression of several glycolytic enzymes, including HK2, glucose-6-phosphate isomerase (GPI), PFK1, aldolase (ALDO), fructose bisphosphate (FBP), triose phosphate isomerase (TPI), GAPDH, phosphoglycerate kinase (PGK1), enolase 1 (ENO1), pyruvate kinase, muscle (PKM), and LDHA (9-12).In addition, MYC augments glutamine catabolism by inducing the LDH and its roles in tumorigenesis LDH mediates bidirectional conversion of pyruvate and lactate and is an emerging anticancer target (Figure 2).LDH is a tetramer composed of two different subunits, LDHA and LDHB, which Conflict of interest: The authors have declared that no conflict of interest exists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci69741

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 1,166

Metadata

Authors
Doherty, J. R., & Cleveland, J. L.
Venue
Journal of Clinical Investigation
Published
2013-09-03
Volume
123
Issue
9
Pages
3685-3692
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1964959571
Cited by
1,166
References
106
FWCI
18.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.